The Plain Record

Neutral daily news — clear headlines, complete facts.

Legal

Judge Approves $7.25 Billion Bayer Settlement Over Roundup Cancer Claims

A Missouri judge approved a $7.25 billion settlement for Bayer to resolve thousands of lawsuits alleging its Roundup weed killer caused non-Hodgkin lymphoma.

Published November 20, 2026 at 6:25 PM EST

The short answer

A Missouri judge approved a $7.25 billion settlement for Bayer to resolve thousands of lawsuits alleging its Roundup weed killer caused non-Hodgkin lymphoma. Agrochemical manufacturer Bayer will pay up to $7.25 billion over two decades to resolve thousands of U.S. lawsuits filed by patients who allege the company's weed killer, Roundup, caused them to develop non-Hodgkin lymphoma.

Judge Approves $7.25 Billion Bayer Settlement Over Roundup Cancer Claims

The Facts

Who
Bayer (agrochemical maker), St. Louis Circuit Judge Timothy Boyer, and thousands of U.S. cancer patients.
What
Court approval of a $7.25 billion settlement involving Bayer and Roundup cancer claims.
When
Friday, November 20, 2026
Where
Jefferson City and St. Louis, Missouri
Why
To resolve thousands of legal claims alleging Bayer failed to warn users that Roundup could cause non-Hodgkin lymphoma.

Agrochemical manufacturer Bayer will pay up to $7.25 billion over two decades to resolve thousands of U.S. lawsuits filed by patients who allege the company's weed killer, Roundup, caused them to develop non-Hodgkin lymphoma. A Missouri judge approved the settlement on Friday, Nov. 20, 2026. The plaintiffs argued that the company failed to provide adequate warnings regarding potential cancer risks associated with the product.

The litigation involves glyphosate, the active ingredient in Roundup since its 1974 debut by Monsanto, which Bayer acquired in 2018. While the World Health Organization's International Agency for Research on Cancer classified glyphosate as "probably carcinogenic" in 2015, the U.S. Environmental Protection Agency (EPA) has maintained that the chemical is unlikely to cause cancer in humans when used as directed. Approximately 200,000 Roundup-related claims have been filed, many by residential users, leading Bayer to remove glyphosate from residential versions of the product.

Under the terms approved by St. Louis Circuit Judge Timothy Boyer, the nationwide settlement covers both currently ill individuals and those diagnosed in the future who were exposed to the product before February 2026. Individual payouts are expected to average between $10,000 and $165,000, depending on age, severity of illness, and type of exposure. The settlement includes $600 million for attorneys' fees and follows a June U.S. Supreme Court ruling that found Bayer cannot be sued in state courts on claims it failed to warn about cancer because federal regulations do not require such a label.

The settlement affects thousands of cancer patients and their families, as well as agricultural, industrial, and turf workers who have been exposed to the herbicide. Individual compensation is determined by specific criteria: workers under age 60 with aggressive forms of lymphoma may receive an average of $165,000, while those diagnosed at age 78 or older would receive approximately $10,000. These payments, distributed from a special fund over 21 years, are in addition to $16 billion Bayer previously allocated for Roundup-related legal costs.

For the affected individuals, the settlement provides compensation in exchange for waiving certain legal rights, including the ability to seek punitive damages. Participants would otherwise face the uncertainty of trial following the Supreme Court's ruling that federal regulations preempt state-level labeling requirements. While some attorneys for the plaintiffs called the deal a necessary alternative to receiving nothing, others criticized the amounts as inadequate given that the glyphosate-based version of the product remains available in the agricultural market.

For Bayer, the court-approved deal is intended to provide financial certainty and mitigate future litigation risks that had led the company to consider withdrawing Roundup from U.S. agricultural markets. Judge Boyer noted that the company might have sought bankruptcy protection if the settlement had been rejected. The agreement establishes a long-term payment structure for up to 21 years. Although the judge has granted final approval, the decision remains subject to potential appeals.

Timeline of what happened

Key dates and decisions, in the order they occurred.

  1. 1974

    Monsanto debuts Roundup weed killer

  2. 2015

    WHO agency classifies glyphosate as 'probably carcinogenic'

  3. 2018

    Bayer acquires Monsanto and Roundup portfolio

  4. February 2026

    Settlement proposed to address Roundup litigation

  5. June 2026

    U.S. Supreme Court rules on state-level labeling claims

  6. October 2026

    Missouri jury sides with Bayer in first post-Supreme Court verdict

  7. November 20, 2026

    Missouri judge grants final approval to $7.25 billion settlement

Summaries are written by The Plain Record to state the facts of a story plainly and without political slant. Drafted with AI assistance and checked against the source record before publication. See how we report, or report a correction.

← Back to the front page

Questions readers ask

What happened: Judge Approves $7.25 Billion Bayer Settlement Over Roundup Cancer Claims?

Court approval of a $7.25 billion settlement involving Bayer and Roundup cancer claims.

Who is involved?

Bayer (agrochemical maker), St. Louis Circuit Judge Timothy Boyer, and thousands of U.S. cancer patients.

When did this happen?

Friday, November 20, 2026

Where did this happen?

Jefferson City and St. Louis, Missouri

Why does this matter?

To resolve thousands of legal claims alleging Bayer failed to warn users that Roundup could cause non-Hodgkin lymphoma.